Preclinical News and Research

RSS
DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida announces presentations on bioerodible technologies for degenerative eye disease

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

Immunogen reports a net loss of $12.1 million in third quarter 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime to acquire Singapore-based company, ES Cell International

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Remote heart rhythm treatment procedure using a robotic arm

Remote heart rhythm treatment procedure using a robotic arm

Geron reports net loss of $16.6M for first-quarter 2010

Geron reports net loss of $16.6M for first-quarter 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Study: Curcumin nanoparticles limit toxicity of cancer therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.